Document Detail

Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer.
MedLine Citation:
PMID:  10969446     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: A study of tamoxifen, ifosfamide, epirubicin and cisplatin (TIEP) chemotherapy was conducted in patients with extensive-disease, small-cell lung cancer (SCLC) to assess response and toxicity. METHODS: From November, 1997, to February, 1999, 11 patients were treated, including six chemo-naïve patients and five patients previously treated with cisplatin plus etoposide (EP). The treatment regimen included tamoxifen 60 mg twice daily orally on days 1 to 3, ifosfamide 3 g/m2 intravenous (i.v.) infusion for 60 minutes with mesna on day 2, epirubicin 50 mg/m2 i.v. bolus on day 2 and cisplatin 60 mg/m2 i.v. for 60 minutes on day 2, every 4 weeks for up to six cycles. RESULTS: All patients were evaluated for toxicity and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 leukopenia or neutropenia occurred in all patients during treatment. Two patients (18.2%) experienced fever in association with the neutropenia, one of whom died of sepsis. Grade 3 anemia occurred in two patients (18.2%) during treatment. Toxicities other than neutropenia and anemia were limited. After two cycles of treatment, five of six chemo-naïve patients (83%), and one of five previously treated patients (20%) attained a partial response (overall 54.5%, 95% confidence interval 25%-83.9%). Median survival time was 8.5 and 6 months in chemo-naïve and previously EP-treated patients, respectively. The response rate and median survival time in chemo-naïve patients did not improve compared with a previous study of ifosfamide plus etoposide undertaken 4 years earlier. CONCLUSIONS: Although TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with extensive-disease SCLC, it showed no remarkable benefit compared with other regimens used in chemo-naïve patients. The 20% response rate and median survival of 6 months in EP-treated patients deserve further study.
Y M Chen; R P Perng; K Y Yang; H W Wu; W C Lin; J M Liu; C M Tsai; J Whang-Peng
Related Documents :
8940736 - Primary malignant fibrous histiocytoma of the lung in a child: a case report and review...
17710206 - Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice g...
24674086 - Postmastectomy chest wall radiotherapy with single low-energy electron beam: an assessm...
1743556 - Etoposide (vp-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurr...
18809226 - Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer:...
2467846 - Treatment of nonmetastatic gestational trophoblastic disease with sequential intramuscu...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  Zhonghua yi xue za zhi = Chinese medical journal; Free China ed     Volume:  63     ISSN:  0578-1337     ISO Abbreviation:  Zhonghua Yi Xue Za Zhi (Taipei)     Publication Date:  2000 Aug 
Date Detail:
Created Date:  2000-09-14     Completed Date:  2000-09-14     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  0005327     Medline TA:  Zhonghua Yi Xue Za Zhi (Taipei)     Country:  CHINA    
Other Details:
Languages:  eng     Pagination:  605-11     Citation Subset:  IM    
Chest Department, Taipei Veterans General Hospital, National Yang-Ming University School of Medicine, Taiwan, ROC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Carcinoma, Small Cell / drug therapy*,  mortality
Lung Neoplasms / drug therapy*,  mortality
Middle Aged

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Problem-based, small-group tutorial learning in clinical neurology for second-year medical students.
Next Document:  Cardiac manifestations of fatal enterovirus infection during the 1998 outbreak in Taiwan.